Cargando…

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

BACKGROUND: Because the general population is largely naive to H5N1 influenza, antibodies generated to H5 allow analysis of novel influenza vaccines independent of background immunity from previous infection. We assessed the safety and immunogenicity of DNA encoding H5 as a priming vaccine to improv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ledgerwood, Julie E, Wei, Chih-Jen, Hu, Zonghui, Gordon, Ingelise J, Enama, Mary E, Hendel, Cynthia S, McTamney, Patrick M, Pearce, Melissa B, Yassine, Hadi M, Boyington, Jeffrey C, Bailer, Robert, Tumpey, Terrence M, Koup, Richard A, Mascola, John R, Nabel, Gary J, Graham, Barney S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2011
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185472/ https://www.ncbi.nlm.nih.gov/pubmed/21975270 http://dx.doi.org/10.1016/S1473-3099(11)70240-7

Ejemplares similares

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
por: DeZure, Adam D., et al.
Publicado: (2017)

Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults
por: Crank, Michelle C., et al.
Publicado: (2015)

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses
por: Koup, Richard A., et al.
Publicado: (2010)

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2015)

DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
por: Graham, Barney S., et al.
Publicado: (2013)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera
por: Yassine, Hadi M., et al.
Publicado: (2018)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

Structural and genetic basis for development of broadly neutralizing influenza antibodies
por: Lingwood, Daniel, et al.
Publicado: (2012)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen
por: Casazza, JP, et al.
Publicado: (2009)

DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial
por: Ledgerwood, Julie E., et al.
Publicado: (2015)

Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2014)

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
por: Martin, Julie E., et al.
Publicado: (2008)

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial
por: Carter, Cristina, et al.
Publicado: (2019)

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial
por: Houser, Katherine V., et al.
Publicado: (2018)

Reconstituted B cell receptor signaling reveals carbohydrate-dependent mode of activation
por: Villar, Rina F., et al.
Publicado: (2016)

Profile of patients with chemical injury and sensitivity.
por: Ziem, G, et al.
Publicado: (1997)

Hyperglycosylated resurfaced stabilized GP120 core as an immunogen elicits antibodies targeted at the CD4-binding site
por: Dai, K, et al.
Publicado: (2012)

Transforming epitope-specific gp120 monomer-based probes into immunogens with N-linked glycan masking
por: Chuang, G, et al.
Publicado: (2012)

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
por: Gaudinski, Martin R., et al.
Publicado: (2018)

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
por: Gaudinski, Martin R, et al.
Publicado: (2018)

Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice
por: Cayatte, Corinne, et al.
Publicado: (2017)

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial
por: Houser, Katherine V., et al.
Publicado: (2022)

Author Correction: Next-generation influenza vaccines: opportunities and challenges
por: Wei, Chih-Jen, et al.
Publicado: (2020)

Next-generation influenza vaccines: opportunities and challenges
por: Wei, Chih-Jen, et al.
Publicado: (2020)

Vaccine Development in the Twenty‐First Century: Changing Paradigms for Elusive Viruses
por: Graham, B S, et al.
Publicado: (2009)

Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus
por: Boyington, Jeffrey C., et al.
Publicado: (2016)

Comparative Efficacy of Hemagglutinin, Nucleoprotein, and Matrix 2 Protein Gene-Based Vaccination against H5N1 Influenza in Mouse and Ferret
por: Rao, Srinivas S., et al.
Publicado: (2010)

P14-12. Safety and tolerability of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular, subcutaneous and intradermal administration in healthy adults
por: Enama, ME, et al.
Publicado: (2009)

P19-57 LB. Gene-based vaccination protects against mucosal infection by a heterologous highly pathogenic SIV isolate in rhesus monkeys
por: Letvin, N, et al.
Publicado: (2009)

Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost
por: Levine, Min Z., et al.
Publicado: (2019)

P13-01. Crystal structure and function of a monoclonal antibody against primate CD4 that blocks HIV/SIV infection
por: Pegu, A, et al.
Publicado: (2009)

A scalable and high yielding SARS-CoV-2 spike protein receptor binding domain production process
por: Riguero, Valeria, et al.
Publicado: (2023)

In vivo targeting of HIV gag to dendritic cells in combination with poly ICLC is safe and immunogenic in healthy volunteers
por: Caskey, M, et al.
Publicado: (2012)

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial
por: Houser, Katherine V., et al.
Publicado: (2022)

Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa
por: Jaoko, Walter, et al.
Publicado: (2010)

Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base
por: Corrigan, Angela R., et al.
Publicado: (2021)

Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans
por: Levine, Min Z, et al.
Publicado: (2017)

Asparagine Substitution at PB2 Residue 701 Enhances the Replication, Pathogenicity, and Transmission of the 2009 Pandemic H1N1 Influenza A Virus
por: Zhou, Bin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9hhiij9q5srmd06kl2jrmk5br3